Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8421144 | 0.84 | ACP1 (0.56) | NPC1POLBMAPTHDAC1RAB9A | |
| SCHEMBL8421533 | 0.81 | PABPC1 (0.63) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL13034819 | 0.79 | NPC1 (0.70) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL6719866 | 0.79 | ROCK2 (0.62) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL3627962 | 0.78 | ALDH1A1 (0.64) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL3632246 | 0.78 | ALDH1A1 (0.64) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL8083047 | 0.78 | HDAC1 (0.72) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL29221820 | 0.78 | NPC1 (0.60) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL8420871 | 0.77 | HDAC1 (0.65) | NPC1POLBMEN1MAPTKMT2A | |
| SCHEMBL4960580 | 0.77 | NPC1 (0.77) | NPC1POLBMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847122-B2 | Polymorphs of suberoylanilide hydroxamic acid | MERCK HDAC RESEARCH, LLC (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080249179-A1 | Methods of treating cancer with HDAC inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-10-09 | — | — | US | disclosed |
| US-20080228005-A1 | Polymorphs of suberoylanilide hydroxamic acid | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-18 | — | — | US | disclosed |
| US-20080227862-A1 | Methods of treating cancer with HDAC inhibitors | ATON PHARMA, INC. | 2008-09-18 | — | — | US | disclosed |
| US-7375137-B2 | Methods of treating cancer with HDAC inhibitors | MERCK HDAC RESEARCH, LLC (US) | 2008-05-20 | — | — | US | disclosed |
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | ATON PHARMA, INC. (US) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC1, HDAC4 | NPC1 1123/4885POLB 1223/4885MEN1 4220/4885 |
| US-20080249179-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC9, HDAC1 | NPC1 1351/4885POLB 3321/4885MEN1 2776/4885 |
| US-20080228005-A1 | Polymorphs of suberoylanilide hydroxamic acid | HDAC1, HDAC4, HDAC5 | NPC1 1777/4885POLB 860/4885MEN1 4666/4885 |
| US-20080227862-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC9, HDAC1 | NPC1 1351/4885POLB 3321/4885MEN1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.